Introduction
Background
Schizophrenia is a severe and persistent debilitating psychiatric disorder. It is not well understood and probably consists of several separate illnesses. Symptoms include disturbances in thoughts (or cognitions), mood (or affects), perceptions, and relationships with others. The hallmark symptoms of schizophrenia are the experiences of hallucinations, often of the auditory type, as well as delusions. However, impaired information processing is probably the most harmful symptom. Patients with schizophrenia have lower rates of employment, marriage, and independent living than other people.
Pathophysiology
Neuroimaging studies have demonstrated anatomical abnormalities in patients with schizophrenia. Bilateral ventriculomegaly and decreased brain volume exist in medial temporal areas such as the hippocampus and amygdala.1 Because of the large overlap between the healthy and the schizophrenia brain, these findings are of greater research interest than clinical use.
Interest has also focused on the various connections within the brain rather than localization in one part of the brain. Indeed, neuropsychological studies show impaired information processing in patients with schizophrenia, and MRI studies show anatomic abnormalities in a network of neocortical and limbic regions and interconnecting white matter tracts.2
The first clearly effective antipsychotic drugs, chlorpromazine and reserpine, were structurally different from each other, but they shared antidopaminergic properties. Drugs that diminish the firing rates of mesolimbic dopamine D2 neurons are antipsychotic, and drugs that stimulate these neurons (eg, amphetamines) exacerbate psychotic symptoms. Therefore, abnormalities of the dopaminergic system are thought to exist in patients with schizophrenia; however, little direct evidence supports this. This theory has recently undergone considerable refinement.
Hypodopaminergic activity in the mesocortical system (leading to negative symptoms) and hyperdopaminergic activity in the mesolimbic system (leading to positive symptoms) may exist. Moreover, the newer antipsychotic drugs block both dopamine D2 and 5-hydroxytryptamine (5-HT) receptors. Clozapine, perhaps the most effective antipsychotic agent, is a particularly weak dopamine D2 antagonist. Undoubtedly, other neurotransmitter systems, such as norepinephrine, serotonin, and gamma-aminobutyric acid (GABA), are involved. Some research focuses on the N -methyl-D-aspartate (NMDA) subclass of glutamate receptors because NMDA antagonists, such as phencyclidine hydrochloride and ketamine, can lead to psychotic symptoms in healthy subjects.3
Frequency
International
The prevalence of schizophrenia is approximately 1% worldwide.
Mortality/Morbidity
People with schizophrenia have a 10% lifetime risk of suicide. Mortality is also increased because of medical illnesses, due to a combination of unhealthy lifestyles, side effects of medication, and decreased health care.
Race
No known racial differences exist in the prevalence of schizophrenia. Some research indicates that schizophrenia is diagnosed more frequently in black people than in white people. This finding has been attributed to cultural bias by practitioners.
Sex
The prevalence of schizophrenia is the same in men and women. The onset of schizophrenia is later and the symptomatology is less severe in women than in men. This may be because of the antidopaminergic influence of estrogen.
Age
The onset of schizophrenia usually occurs in adolescence, and symptoms remit somewhat in older patients. Most of the deterioration that occurs in patients with schizophrenia occurs in the first 5-10 years of the illness and is usually followed by decades of relative stability, although a return to baseline is unusual.
Clinical
History
- Information about the medical and psychiatric history of the family, details about pregnancy and early childhood, history of travel, and history of medications and substance abuse are all important. This information is helpful in ruling out other causes of psychotic symptoms.
- The patient usually had an unexceptional childhood but began to experience a change in personality and a decrease in academic, social, and interpersonal functioning during mid-to-late adolescence. In retrospect, family members may describe the person with schizophrenia as a physically clumsy and emotionally aloof child.
- Usually, about a year passes between the onset of these vague symptoms and the first visit to a psychiatrist.
- The first psychotic episode usually occurs between the late teenage years and mid 30s.
Physical
Findings on a general physical examination are usually not contributory. This examination is necessary to rule out other illnesses
A neurologic examination is important to evaluate the patient for movement disorders, particularly those that might indicate Wilson disease or Huntington disease, or other disorders that are present before the initiation of antipsychotic medications. Some patients with schizophrenia have motor disturbances before exposure to antipsychotic agents.
Mental Status Examination
The symptoms of schizophrenia may be divided into the 3 following domains:
- Positive symptoms: These include psychotic symptoms, such as hallucinations, which are usually auditory; delusions; and disorganized speech and behavior.
- Negative symptoms: These include a decrease in emotional range, poverty of speech, loss of interests, and loss of drive. The person with schizophrenia has tremendous inertia.
- Cognitive symptoms: These include deficits in attention and executive functions such as the ability to organize and abstract.
Patients who are schizophrenic may show a repertoire of strange poorly understood behaviors that are rarely observed in others. These include water drinking to the point of intoxication, staring at oneself in the mirror, stereotyped behaviors, hoarding useless objects, self-mutilation, and a disturbed wake-sleep cycle. They often experience difficulty dealing with change.
- On a detailed mental status examination in the office, the following observations are often made when talking with a person with schizophrenia:
- The schizophrenic person may be dressed oddly and pay insufficient attention to personal hygiene.
- This person may be unduly suspicious of the examiner and endorse a variety of odd beliefs or delusions.
- He or she often has a flat affect, meaning that they have little range of expressed emotion.
- The person may admit to hallucinations or attend to auditory or visual stimuli not apparent to the examiner.
- The person may show thought blocking in which long pauses occur before answers to questions or odd pauses in the middle of answers.
- Conversation and initiation of speech may be limited.
- Schizophrenia patients may demonstrate their difficulty in abstract thinking by not being able to understand common proverbs. Alternatively, the patient may produce an esoteric or intriguing interpretation that turns out to be idiosyncratic and meaningless on further investigation.
- The speech of the schizophrenic person can be circumstantial, meaning that the person takes a long time and uses a lot of words in answering a question, or tangential, meaning the person speaks at length but never actually answers the question.
- The patient often shows poor attention, disorganized thinking, and stereotyped or perseverative thinking.
- The patient may make odd movements (which may or may not be related to neuroleptic medication).
- The person has no insight into his or her problems (anosognosia).
- The person should always be asked about suicide, violence, and homicide — whether or not they are having any thoughts about hurting or harming themselves or others in any way and whether or not they are hearing voices telling them to do so.
- Orientation (knowing their own identity, where he or she is, and what the time is) is usually intact.
- According to the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), the patient must have experienced at least 2 of the following symptoms: delusions, hallucinations, disorganized speech, disorganized or catatonic behavior, or negative symptoms. Only 1 symptom is required if the delusions are bizarre or if auditory hallucinations occur in which the voices comment in an ongoing manner on the person's behavior, or if 2 or more voices are talking with each other. The patient must experience at least 1 month of symptoms (or less if successfully treated) during a 6-month period, and social or occupational deterioration problems occur over a significant amount of time. These problems must not be attributable to another condition for the diagnosis of schizophrenia to be made.4
Causes
The causes of schizophrenia are not known. Most likely, at least 2 groups of risk factors exist: genetic and perinatal.- Genetic
- The risk of schizophrenia is elevated in biological relatives of patients who are schizophrenic but not in adopted relatives.
- The risk of schizophrenia in first-degree relatives of people with schizophrenia is 10%.
- If both parents are schizophrenic, the risk of schizophrenia in their child is 40%.
- Concordance for schizophrenia is about 10% for dizygotic twins and 40-50% for monozygotic twins.
- Many genetic loci that increase the risk for schizophrenia probably exist.
- Schizophrenia has been associated with left and mixed handedness.
- The risk of schizophrenia is elevated in biological relatives of patients who are schizophrenic but not in adopted relatives.
- Perinatal: Much research concerning the association of pregnancy and birth complications with schizophrenia has been conducted. These perinatal risk factors suggest that schizophrenia is a neurodevelopmental disorder, perhaps sometimes beginning in utero or at birth, although the exact nature is far from understood.
- Women who are malnourished or who have certain viral illnesses during their pregnancy may be at greater risk of giving birth to children who later develop schizophrenia.
- Children born to Dutch mothers who were malnourished during World War II have a high incidence of schizophrenia.
- The 1957 influenza A2 epidemics in Japan, England, and Scandinavia resulted in an increase in schizophrenia in the offspring of women who developed this flu during their second trimester.
- Women in California who were pregnant between 1959 and 1966 were more likely to have children who developed schizophrenia if they had flu in the first trimester of their pregnancy.5
- Obstetric complications may be associated with a higher incidence of schizophrenia.
- Children born in the winter months may be at greater risk for developing schizophrenia.
- Women who are malnourished or who have certain viral illnesses during their pregnancy may be at greater risk of giving birth to children who later develop schizophrenia.
More on Schizophrenia |
Overview: Schizophrenia |
| Differential Diagnoses & Workup: Schizophrenia |
| Treatment & Medication: Schizophrenia |
| Follow-up: Schizophrenia |
| References |
| Next Page » |
References
Wright IC, Rabe-Hesketh S, Woodruff PW, et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. Jan 2000;157(1):16-25. [Medline].
Sigmundsson T, Suckling J, Maier M, et al. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry. Feb 2001;158(2):234-43. [Medline].
Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. Jan-Feb 1996;3(5):241-53. [Medline].
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th ed. Washington, DC: American Psychiatric Press; 2000.
Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry. Aug 2004;61 (8):774-80. [Medline].
Cummings JL, Gosenfeld LF, Houlihan JP, McCaffrey T. Neuropsychiatric disturbances associated with idiopathic calcification of the basal ganglia. Biol Psychiatry. May 1983;18(5):591-601. [Medline].
Rosebush PI, MacQueen GM, Clarke JT, et al. Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. J Clin Psychiatry. Aug 1995;56(8):347-53. [Medline].
Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry. May 1994;51(5):375-82. [Medline].
Reuler JB, Girard DE, Cooney TG. Current concepts. Wernicke''s encephalopathy. N Engl J Med. Apr 18 1985;312(16):1035-9. [Medline].
Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet. Apr 1 2000;355(9210):1155-6. [Medline].
Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic drugs and venous thromboembolism. Lancet. Jul 15 2000;356(9225):252. [Medline].
Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. Suppl 1 2007;68:20-7. [Medline].
Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med. Mar 14 1991;324(11):746-54. [Medline].
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. May 2006;163:790-9. [Medline].
Allison DB, Mentore JL, Heo M. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. Nov 1999;156(11):1686-96. [Medline].
Auquier P, Lancon C, Rouillon F, Lader M, Holmes C. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf. Dec 2006;15:873-9. [Medline].
Bustillo J, Lauriello J, Horan W, et al. The psychosocial treatment of schizophrenia: an update. Am J Psychiatry. Feb 2001;158(2):163-75. [Medline].
Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry. Dec 1975;132(12):1237-45. [Medline].
Frankenburg FR. Choices in antipsychotic therapy in schizophrenia. Harv Rev Psychiatry. Jan-Feb 1999;6(5):241-9. [Medline].
Ho BC, Andreasen NC. Long delays in seeking treatment for schizophrenia. Lancet. Mar 24 2001;357(9260):898-900. [Medline].
Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. Nov 19 1994;344(8934):1398-402. [Medline].
Kelly M, Newstead L. Family Intervention in routine practice: it is possible!. J Psychiatr Ment Health Nurs. Feb 2004;11(1):64-72. [Medline].
Kety SS, Wender PH, Jacobsen B, et al. Mental illness in the biological and adoptive relatives of schizophrenic adoptees. Replication of the Copenhagen Study in the rest of Denmark. Arch Gen Psychiatry. Jun 1994;51(6):442-55. [Medline].
Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24(1):1-10. [Medline].
Lishman WA. Organic Psychiatry. London, England: Blackwell Science Publication; 1987.
May PR, Tuma AH, Dixon WJ, et al. Schizophrenia. A follow-up study of the results of five forms of treatment. Arch Gen Psychiatry. Jul 1981;38(7):776-84. [Medline].
Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord. Sep 1982;4(3):173-93. [Medline].
Salokangas RK. Medical problems in schizophrenia patients living in the community (alternative facilities). Curr Opin Psychiatry. Jul/2007;20:402-5. [Medline].
Torrey EF, Bowler AE, Rawlings R, Terrazas A. Seasonality of schizophrenia and stillbirths. Schizophr Bull. 1993;19(3):557-62. [Medline].
Further Reading
Keywords
dementia praecox, auditory hallucinations, impaired information processing, delusions, disorganized speech, disorganized behavior, psychiatric disorders, thought disturbances, distorted thinking, mental illness, psychosis, mental disorder, delusions, depression, mania, manic depressive, major depressive disorder, mood disorder
Overview: Schizophrenia